Sanofi (NYSE:SNY) Given a $48.00 Price Target at Cowen

Cowen set a $48.00 target price on Sanofi (NYSE:SNY) in a research note released on Monday, December 18th. The brokerage currently has a hold rating on the stock.

A number of other equities research analysts have also weighed in on the stock. JPMorgan Chase & Co. reiterated a neutral rating on shares of Sanofi in a research note on Thursday, December 14th. Bank of America downgraded shares of Sanofi from a buy rating to a neutral rating in a research report on Wednesday, December 6th. Morgan Stanley downgraded shares of Sanofi from an overweight rating to an underweight rating in a research report on Friday, December 1st. Barclays raised shares of Sanofi from an underweight rating to an equal weight rating in a report on Wednesday, November 15th. Finally, Zacks Investment Research downgraded shares of Sanofi from a hold rating to a strong sell rating in a report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company’s stock. Sanofi has a consensus rating of Hold and an average price target of $51.50.

Shares of Sanofi (SNY) traded up $0.77 during midday trading on Monday, reaching $44.78. 1,659,802 shares of the company were exchanged, compared to its average volume of 1,200,000. The stock has a market cap of $111,920.00, a price-to-earnings ratio of 20.64, a P/E/G ratio of 2.54 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59. Sanofi has a 52 week low of $39.42 and a 52 week high of $50.65.

A number of institutional investors have recently bought and sold shares of SNY. Geode Capital Management LLC raised its position in Sanofi by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 43,684 shares of the company’s stock worth $1,976,000 after purchasing an additional 1,448 shares during the period. Opus Capital Group LLC purchased a new position in shares of Sanofi during the second quarter worth approximately $222,000. Blair William & Co. IL increased its position in shares of Sanofi by 42.7% during the second quarter. Blair William & Co. IL now owns 18,824 shares of the company’s stock worth $902,000 after acquiring an additional 5,635 shares during the period. MAI Capital Management purchased a new position in shares of Sanofi during the second quarter worth approximately $214,000. Finally, ProVise Management Group LLC increased its position in shares of Sanofi by 62.5% during the second quarter. ProVise Management Group LLC now owns 130,513 shares of the company’s stock worth $6,253,000 after acquiring an additional 50,175 shares during the period. 9.08% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Sanofi (NYSE:SNY) Given a $48.00 Price Target at Cowen” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/13/cowen-reiterates-48-00-price-target-for-sanofi-sny.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply